Overview

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)

Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Assessment of efficacy of azacitidine to prevent a relapse
Phase:
Phase 2
Details
Lead Sponsor:
Technische Universität Dresden
Treatments:
Azacitidine